Vecuronium in renal failure

[1]  I. G. Marshall,et al.  Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat. , 1983, British journal of anaesthesia.

[2]  J. Hunter,et al.  Use of atracurium in patients with no renal function. , 1982, British journal of anaesthesia.

[3]  D. Bevan,et al.  Clinical experience with org nc45 (norcuron) as the sole muscle relaxant , 1982, Canadian Anaesthetists' Society journal.

[4]  H. S. Chadwick.  RELATIVE LIDOCAINE AND BUPIVACAINE TOXICITY IN VENTILATED CATS , 1982 .

[5]  D. Stanski,et al.  Pharmacokinetics and Pharmacodynamics of d‐Tubocurarine in Infants, Children, and Adults , 1982, Anesthesiology.

[6]  P. Lilleaasen,et al.  Dose-response relation for atracurium, ORG NC 45 and pancuronium. , 1982, British journal of anaesthesia.

[7]  R. Miller,et al.  Renal and Biliary Elimination of Vecuronium (ORG NC 45) and Pancuronium in Rats , 1982, Anesthesia and analgesia.

[8]  F. Donati,et al.  Antagonism of pancuronium in renal failure: no recurarization. , 1982, British journal of anaesthesia.

[9]  R. Miller,et al.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. , 1981, British journal of anaesthesia.

[10]  R. Matteo,et al.  Pharmacokinetics and Pharmacodynamics of Metocurine in Humans with and without Renal Failure , 1981, Anesthesiology.

[11]  C. Shanks,et al.  Gallamine disposition in surgical patients with chronic renal failure. , 1981, British journal of clinical pharmacology.

[12]  R. Miller,et al.  Clinical Pharmacology of ORG NC45 (NorcuronTM): A New Nondepolarizing Muscle Relaxant , 1981, Anesthesiology.

[13]  N. Krieg,et al.  Relative potency of ORG NC 45, pancuronium, alcuronium and tubocurarine in anaesthetized man. , 1981, British journal of anaesthesia.

[14]  N. Krieg,et al.  RELATIVE POTENCY OF ORG NC 45, PANCURONIUM, ALCURONIUM AND TUBOCURARINE IN ANAESTHETIZED MAN , 1980 .

[15]  D. S. Savage,et al.  The Emergence of ORG NC 45, 1- [(2β,3α, 5α,16β, 17β)-3, 17-BIS(Acetyloxy)-2-(1-Piperidinyl)-Androstan-16-YL]-1-Methylpiperidinium Bromide, from the Pancuronium Series , 1980 .

[16]  A. Gissen,et al.  Determination of d-Tubocurarine by Liquid Chromatography , 1979 .

[17]  M. Houwertjes,et al.  RENAL ELIMINATION OF ORG-NC45 AND PANCURONIUM , 1979 .

[18]  L. Benet,et al.  The pharmacokinetics of d-tubocurarine in man with and without renal failure. , 1977, The Journal of pharmacology and experimental therapeutics.

[19]  D. Cullen,et al.  Renal failure and postoperative respiratory failure: recurarization? , 1976, British journal of anaesthesia.

[20]  H. H. Ali,et al.  Stimulus frequency in the detection of neuromuscular block in humans. , 1970, British journal of anaesthesia.

[21]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.